Name: | Mário Manuel da Silva Leite de Sousa |
Sigla: | MMSLS |
Estado: | Active |
R-000-CYN | |
0000-0002-3009-3290 | |
5118-4AC0-9709 | |
A-7340-2019 | |
57908382000 |
Email Institucional: | msousaicbas.up.pt |
Extensão Telefónica: | 5246 |
Telf.Alt.: | 220428246 |
|
Cargo | Data de Início |
---|---|
Member of the Scientific Board | 2023-06-27 |
Laboratory Manager Biologia Celular | 2019-02-08 |
E-mail: msousa@icbas.up.pt
ORCID ID: https://orcid.org/0000-0002-3009-3290
CIÊNCIA ID: 5118-4AC0-9709
Portuguese Physicians Order Nº: 30027
Mário Sousa is a physician and full professor. He obtained his medical and PhD degree at ICBAS-School of Medicine and Biomedical Sciences, University of Porto / Centro Hospitalar Universitário do Porto (Hospital Geral de Santo António), his medical specialization at the American Hospital of Paris and his post-doctorate at INSERM 351, Clamart, France. He leads the Biology and Genetics of Reproduction/Molecular and Cellular Medicine group at UMIB. He discovered the mechanism of human oocyte activation at fertilization; the genes responsible for Sertoly cell only syndrome and Hypospermatogenesis in the Y chromosome (in collaboration with Germany); and first described imprinting defects in the male germ line. He developed and implemented new techniques in the field of reproductive medicine, such as intracytoplasmic sperm injection, round spermatid sperm injection and in-vitro maturation of immature germ cells. He introduced in Portugal the preimplantation genetic testing, with the first application to familiar amyloidotic polyneuropathy. He participated in the implementation of governmental policies in Portugal in the field of reproductive medicine. He has supervised/cosupervised 30 PhD students, 46 MSc students, 8 post-doctoral students and 25 research projects, and received 65 prizes. He has published 476 international articles, with more than 8619 SCI with an h-Index of 49 and i-Index of 160. His main research activities are translated medicine in the fields of human reproductive medicine and respiratory diseases. His inclusion in the “World’s Top 2% Scientists list” is another distinction that demonstrates the importance of his work in the fields of reproductive medicine and translational medicine.